Undetected anogenital sexually transmitted infections among young adults living with HIV and receiving antiretroviral therapy: Implications for HIV treatment as prevention
Restricted accessResearch articleFirst published online January, 2022
Undetected anogenital sexually transmitted infections among young adults living with HIV and receiving antiretroviral therapy: Implications for HIV treatment as prevention
Undetected sexually transmitted infections (STIs) pose health threats to people living with HIV and when combined with uncontrolled HIV can amplify HIV transmission. The current study screened 174 self-identified men under age 36 living with HIV and receiving antiretroviral therapy (ART) for urethral and rectal incident chlamydia and gonorrhea infections. Participants were also screened for biomarkers indicating alcohol and other drug use, subclinical genital inflammation, and HIV viral load. ART adherence and sexual behaviors were also assessed prospectively over 1 month. Results detected an undiagnosed STI in 32 (18%) individuals. Participants with a previously undetected STI had significantly greater HIV viremia than those who did not have an STI after controlling for several confounding variables. Participants with an undetected STI also engaged in greater condomless anal intercourse with HIV negative and unknown status partners, including partners to whom they had not disclosed their HIV status. These findings show that undetected STI are associated with incomplete ART adherence and unsuppressed HIV, all of which are important for preventing HIV transmission.
KreiselKMSpicknallIHGarganoJW, et al.Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis2021; 48(4): 208–214.
3.
KalichmanSCPellowskiJTurnerC. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect2011; 87(3): 183–190.
4.
TuddenhamSGhanemKGGeboKA, et al.Gonorrhoea and chlamydia in persons with HIV: number needed to screen. Sex Transm Infect2019; 95(5): 322–327.
5.
PingLHCohenMSHoffmanI, et al.Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol2000; 74(19): 8946–8952.
6.
CopeABPowersKAKurucJD, et al.Ongoing HIV transmission and the HIV care continuum in North Carolina. PLoS One2015; 10(6): e0127950.
7.
ChitneniPMatthewsLT. The other U = U: untested and untreated genital tract inflammation in people living with and exposed to human immunodeficiency virus. J Infect Dis2021; 224(1): 1–4, DOI: 10.1093/infdis/jiab074.
8.
WallKMKaritaENyombayireJ, et al.Genital abnormalities, hormonal contraception, and human immunodeficiency virus transmission risk in rwandan serodifferent couples. J Infect Dis2021; 224(1): 81–91, DOI: 10.1093/infdis/jiab071.
9.
BlishCAMcClellandRSRichardsonBA, et al.Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. J Acquir Immune Defic Syndr2012; 61(4): 436–440.
10.
WallKMKilembeWVwalikaB, et al.Risk of heterosexual HIV transmission attributable to sexually transmitted infections and non-specific genital inflammation in Zambian discordant couples, 1994-2012. Int J Epidemiol2017; 46(5): 1593–1606.
11.
StorimJVerheyenJWolffE, et al.Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections-a cross-sectional, single-center study. Sex Transm Infect2019; 95(2): 95–98.
12.
HeiligenbergMLutterRPajkrtD, et al.Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men. Clin Vaccin Immunol2013; 20(10): 1517–1523.
13.
SolomonHMoraesANWilliamsDB, et al.Prevalence and correlates of active syphilis and HIV co-Infection among sexually active persons aged 15-59 years in Zambia: results from the Zambia population-based HIV impact assessment (ZAMPHIA) 2016. PLoS One2020; 15(7): e0236501.
14.
CulbrethRSwahnMHSalazarLF, et al.Risk factors associated with HIV, sexually transmitted infections (STI), and HIV/STI co-infection among youth living in the slums of Kampala, Uganda. AIDS Behav2020; 24(4): 1023–1031.
15.
LuppiCGGomesSECSilvaRJCD, et al.Factors associated with HIV co-infection in cases of acquired syphilis reported in a reference center for sexually transmitted diseases and AIDS in the municipality of São Paulo, Brazil, 2014. Epidemiol Serv Saude2018; 27(1): e20171678.
16.
DaiWLuoZXuR, et al.Prevalence of HIV and syphilis co-infection and associated factors among non-commercial men who have sex with men attending a sexually transmitted disease clinic in Shenzhen, China. BMC Infect Dis2017; 17(1): 86.
17.
RitchwoodTDFordHDeCosterJ, et al.Risky sexual behavior and substance use among adolescents: a meta-analysis. Child Youth Serv Rev2015; 52: 74–88.
18.
ClaxtonSEDeLucaHKvan DulmenMH. The association between alcohol use and engagement in casual sexual relationships and experiences: a meta-analytic review of non-experimental studies. Arch Sex Behav2015; 44(4): 837–856.
19.
Scott-SheldonLACareyKBCunninghamK, et al.Alcohol use predicts sexual decision-making: a systematic review and meta-analysis of the experimental literature. AIDS Behav2016; 20(Suppl 1): S19–S39.
20.
HendershotCSStonerSAPantaloneDW, et al.Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr2009; 52(2): 180–202.
21.
VellozaJKempCGAunonFM, et al.Alcohol use and antiretroviral therapy non-adherence among adults living with HIV/AIDS in sub-Saharan Africa: a systematic review and meta-analysis. AIDS Behav2020; 24(6): 1727–1742.
22.
MishraSNaikBVenugopalB, et al.Syphilis screening among female sex workers in Bangalore, India: comparison of point-of-care testing and traditional serological approaches. Sex Transm Infect2010; 86(3): 193–198.
23.
MabeyDPeelingRWBallardR, et al.Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis. Sex Transm Infect2006; 82(Suppl 5): v13–6.
24.
AndersonBLWangCCDelongAK, et al.Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis2008; 47(9): 1216–1221.
25.
KutterDvan OudheusdenAPHilversAG, et al.[A new test-strip for demonstrating erythrocytes and haemoglobin in urine (author's transl)]. Dtsch Med Wochenschr1974; 99(46): 2332–2335.
26.
Andresen-StreichertHMüllerAGlahnA, et al.Alcohol biomarkers in clinical and forensic contexts. Dtsch Arztebl Int2018; 115: 309–315.
27.
BangsbergDRHechtFMCharleboisED, et al.Comparing objective measures of adherence to HIV antiretroviral therapy: Electronic medication monitors and unannounced pill counts. AIDS Behav2001; 5: 275–281.
28.
KalichmanSCAmaralCMCherryC, et al.Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials2008; 9: 298–308.
29.
KalichmanSCAmaralCMStearnsH, et al.Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med2007; 22: 1003–1006.
30.
BangsbergDRDeeksSG. Is average adherence to HIV antiretroviral therapy enough?. J Gen Intern Med2002; 17(10): 812–813.
31.
ParientiJJBarrail-TranADuvalX, et al.Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother2013; 57(5): 2265–2271.
TangNPahalawattaVFrankA, et al.HIV-1 viral load measurement in venous blood and fingerprick blood using Abbott RealTime HIV-1 DBS assay. J Clin Virol2017; 92: 56–61.
34.
BernhardtJMUsdanSMaysD, et al.Alcohol assessment among college students using wireless mobile technology. J Stud Alcohol Drugs2009; 70(5): 771–775.
35.
McAuliffeTLDiFranceiscoWReedBR. Low numeracy predicts reduced accuracy of retrospective reports of frequency of sexual behavior. AIDS Behav2010; 14(6): 1320–1329.
36.
ConnerTSBarrettLF. Trends in ambulatory self-report: the role of momentary experience in psychosomatic medicine. Psychosom Med2012; 74(4): 327–337.
37.
SelveyLASlimingsCAdamsE, et al.Incidence and predictors of HIV, chlamydia and gonorrhoea among men who have sex with men attending a peer-based clinic. Sex Health2018; 15(5): 451–459.
38.
ByrdKKHouJGHazenR, et al.Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr2019; 82(3): 245–251.
39.
RosenblumMDeeksSGvan der LaanM, et al.The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE2009; 4(9): e7196.
40.
LimaVDBangsbergDRHarriganPR, et al.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr2010; 55(4): 460–465.
41.
CrepazNTangTMarksG, et al.Durable viral suppression and transmission risk potential among persons with diagnosed HIV infection: United States, 2012-2013. Clin Infect Dis2016; 63(7): 976–983.
42.
FauciASRedfieldRRSigounasG, et al.Ending the HIV Epidemic: a plan for the United States. JAMA2019; 321(9): 844–845.
43.
HennyKDJeffriesWL. Ending the HIV epidemic in the United States must start with the South. AIDS Behav2019; 23(Suppl 3): 221–223.
44.
The LancetL. Ending HIV in the USA. Lancet2019; 393(10175): 960.
45.
ValdiserriROHoltgraveDR. Ending HIV in America: not without the power of community. AIDS Behav2019; 23(11): 2899–2903.
46.
CatesW. HPTN 052 and the future of HIV treatment and prevention. Lancet2011; 378(9787): 224–225.
47.
CohenMSMcCauleyMGambleTR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS2012; 7(2): 99–105.
48.
CohenMSChenYQMcCauleyM, et al.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med2011; 365(6): 493–505.
49.
EatonEFHudakKMuznyCA. Budgetary impact of compliance with STI screening guidelines in persons living with HIV. J Acquir Immune Defic Syndr2017; 74(3): 303–308.
50.
de BruinMViechtbauerWHospersHJ, et al.Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: implications for the interpretation and comparison of intervention effects. Health Psychol2009; 28(6): 668–674.
51.
ShawSModiRMugaveroM, et al.HIV standard of care for ART adherence and retention in care among HIV Medical Care Providers Across Four CNICS Clinics in the US. AIDS Behav2019; 23(4): 947–956.
52.
KalichmanSCCherryCKalichmanMO, et al.Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health2011; 101(3): 531–538.
53.
KalichmanSCCherryCKalichmanMO, et al.Mobile health intervention to reduce HIV transmission: a randomized trial of behaviorally enhanced hiv treatment as prevention (B-TasP). J Acquir Immune Defic Syndr2018; 78(1): 34–42.
54.
NaarSRoblesGMacDonellKK, et al.Comparative effectiveness of community-based vs clinic-based healthy choices motivational intervention to improve health behaviors among youth living with HIV: a randomized clinical trial. JAMA Netw Open2020; 3(8): e2014650.
